DIAMEDICA THERAPEUTICS INC (DMAC) Stock News

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings

Preview: DiaMedica Therapeutics's Earnings

DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the second quart...

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the first quarte...

DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the fourth quart...

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors

DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics Upcoming Conference Participation

DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024

DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

DiaMedica Therapeutics Announces $11.8 Million Private Placement

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024

DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke